Since markedly elevated IL-6 levels are detected in CSF and plasma of MS patients, and since the cytokine acts as a suppressor of Entpd2 (Yu et al., 2008), it is most likely that the down-regulation of NTPDase2 during EAE is induced by IL-6-mediated suppression of Entpd2. Promoter regions of human ENTPD2 and mouse Entpd2 contain yet another important immune-related regulatory binding site, GATA-3 binding site (Chadwick and Frischauf, 1997). This evidence concerns the gene ENTPD2 and myeloid sarcoma.